PFE catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedNo phase registeredNCT07821216Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims DataPfizer · Alopecia AreataActive, not recruitingPFELead
- Enrollment
- Locked
- Primary completion
- Nov 20, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07494656A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in GermanyPfizer · ATTR-CM (Transthyretin Amyloid Cardiomyopathy)Active, not recruitingPFELead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT00248287PhII ICb With/Without Erbitux in MBC PtsUS Oncology Research · Metastatic Breast CancerActive, not recruitingBMYCollaboratorPFECollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2025Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT01731353FungiScope - A Global Emerging Fungal Infection RegistryUniversity of Cologne · Invasive Fungal Disease
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT02738866Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase InhibitorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Metastatic Breast CancerActive, not recruitingPFECollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT03260023Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M CancersTransgene · HPV-Related CarcinomaActive, not recruitingPFECollaborator
- Enrollment
- Locked
- Primary completion
- Sep 18, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 4NCT07197762MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young AdultsEmory University · Neisseria MeningitidisRecruitingPFECollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT04165317A Study of Sasanlimab in People With Non-muscle Invasive Bladder CancerPfizer · Non-muscle Invasive Bladder CancerActive, not recruitingPFELead
- Enrollment
- Locked
- Primary completion
- Dec 2, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT00715442Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)M.D. Anderson Cancer Center · Renal Cell CarcinomaActive, not recruitingPFECollaborator
- Enrollment
- Locked
- Primary completion
- Dec 4, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06622109A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six MonthsPfizer · Pneumococcal DiseaseActive, not recruitingPFELead
- Enrollment
- Locked
- Primary completion
- Dec 4, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07500506A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease VaccinePfizer · Lyme DiseaseRecruitingPFELead
- Enrollment
- Locked
- Primary completion
- Dec 4, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07721402A Study to Learn About How Different Forms of Study Medicine Prifetrastat Are Taken Up Into the Blood in Healthy AdultsPfizer · Healthy ParticipantRecruitingPFELead
- Enrollment
- Locked
- Primary completion
- Dec 8, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT06994897A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy AdultsPfizer · HealthyActive, not recruitingPFELead
- Enrollment
- Locked
- Primary completion
- Dec 12, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07231991A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver FunctionPfizer · Healthy ParticipantsRecruitingPFELead
- Enrollment
- Locked
- Primary completion
- Dec 4, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT02905318Palbociclib in Patients With Metastatic Castration-Resistant Prostate CancerCanadian Cancer Trials Group · Prostate CancerActive, not recruitingPFECollaborator
- Enrollment
- Locked
- Primary completion
- Apr 29, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT03147287Palbociclib After CDK and Endocrine Therapy (PACE)Dana-Farber Cancer Institute · Metastatic Breast CancerActive, not recruitingPFECollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT04846478Phase Ia/Ib Talazoparib + Tazemetostat for mCRPCDana-Farber Cancer Institute · Metastatic Prostate CancerActive, not recruitingPFECollaborator
- Enrollment
- Locked
- Primary completion
- Sep 25, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT05909397Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast CancerPfizer · Breast CancerActive, not recruitingPFELead
- Enrollment
- Locked
- Primary completion
- Dec 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06495164A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast CancerPfizer · Breast CancerActive, not recruitingPFELead
- Enrollment
- Locked
- Primary completion
- Dec 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06613984Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)Pfizer · COVID-19 VaccinationActive, not recruitingPFELead
- Enrollment
- Locked
- Primary completion
- Dec 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT01396408A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare TumoursCanadian Cancer Trials Group · Advanced Rare TumoursActive, not recruitingPFECollaborator
- Enrollment
- Locked
- Primary completion
- Jul 6, 2015Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT02208869Russian Familial Hypercholesterolemia RegistryRussian Cardiology Research and Production Center · Familial Hypercholesterolemia
- Enrollment
- Locked
- Primary completion
- Dec 31, 2017Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT03728478STep-up and Step-down Therapeutic Strategies in Childhood ARthritiSIstituto Giannina Gaslini · Oligoarthritis, JuvenileActive, not recruitingPFECollaborator
- Enrollment
- Locked
- Primary completion
- Oct 31, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT03737955Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid LeukemiaUniversity of Washington · Acute Myeloid LeukemiaRecruitingPFECollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT03848052Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)UNICANCER · Lung Cancer
- Enrollment
- Locked
- Primary completion
- Oct 24, 2025Actual
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 33 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.